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The Cats-and-Dogs Test: A Tool
to Identify Visuoperceptual
Deficits in Parkinson’s Disease
There are no robust features to predict which patients with
Parkinson’s disease (PD) will develop dementia. Those with
involvement of visual processing regions are at highest risk of
dementia.1-3 However, current measures of visuoperception are
poorly sensitive.4 We have developed a sensitive test of visuo-
perception based on the clinical observation that patients with
PD have difficulty reading distorted CAPTCHA (completely
automated public Turing test to tell computers and humans
apart) images.5
Methods
Participants
Twenty patients with PD and 11 age-matched controls with-
out eye disease or dementia were recruited. Clinical and detailed
neuropsychological assessment was performed (Supplemental
Table 1). Participants gave written informed consent. The study
was approved by the local Research Ethics Committee.
Procedure
Images of cats and dogs were skewed by a variable amount
(11 levels, 0-5 arbitrary units [a.u.]) and combined with white
noise (Fig. 1A and Supplementary Methods). On each trial the
skewed image was shown for 280 milliseconds. Participants
indicated whether the image was a cat or dog using the keypad
(4 runs, each with 100 trials; 25 minutes in total, preceded by a
practice session).
Control Task
Images were prepared as above (but not skewed) with a
varying proportion of visual noise added (11 levels), in a simi-
lar procedure with 2 runs, 100 trials per run, 15 PD patients
and 10 age-matched controls (Fig. 1A; Supplemental Table 2).
Analysis
Demographic and neuropsychological data were compared
using Welch’s t and chi-square tests. For each participant a psy-
chophysical curve was generated for the Cats-and-Dogs test and
control task, a sigmoid curve fitted, and 75% performance
threshold determined (Fig. 1B). Bonferroni-corrected P< 0.05
was considered significant. Linear regression was used to exam-
ine relationships between the Cats-and-Dogs test and other vari-
ables. We used a recently described algorithm, modified to
include available clinical variables, to calculate each partici-
pant’s risk of dementia. This combines cross-sectional data
including age, Movement Disorder Society Unified Parkinson’s
Disease Rating Scale (MDS-UPDRS) motor score, depression,
and REM-sleep behavior scores to calculate the 2-year risk of
cognitive impairment.6
Results
Patients with PD performed worse than controls at identify-
ing skewed images: PD mean threshold, 1.926 0.5 a.u; con-
trols, 2.486 0.26 a.u.; t29.0524.06, P5 0.00034 (Fig. 1C).
There was no other significant difference in cognitive or clinical
tests, including the standard visuoperceptual tests, between PD
patients and controls (excluding MDS-UPDRS; Supplemental
Table 1). Mean reaction times and visual acuity did not differ
significantly between the groups.
There was no difference in the control task (white noise)
between PD patients and controls.
The Cats-and-Dogs test correlated with higher age (estimate,
20.03360.009; P50.00093) and vascular risk, after adjust-
ment for PD (estimate, 20.0266 0.006; P50.021). Even after
age adjustment, it correlated with overall cognitive performance
(estimate, 0.1760.05; P50.0037) and language, assessed with
the Graded Naming Test (estimate, 0.0766 0.017; P5 0.00015;
Fig. 1D) but not standard visuoperceptual tests (Supplemental
Table 5). It also correlated with 2-year cognitive impairment
risk, calculated using cross-sectional data6 (R250.22, P5
0.0078; Supplemental Fig. 1).
Discussion
We present pilot data suggesting that identifying skewed
images in the Cats-and-Dogs test is a sensitive measure of
visuoperception in early-stage PD, with greater sensitivity
than standard cognitive and visuospatial tests.
Performance on the Cats-and-Dogs test correlated with age,
vascular risk, and cognitive performance but not with standard
visuoperception tests, most likely because participants were at
ceiling in these tests. Performance in this test also correlated
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with a prediction score for cognitive impairment in PD, sugges-
ting that it may have utility as an early marker of cognitive
decline, consistent with the literature of PD patients with
involvement of visual-processing regions being at the highest
risk of dementia.1-3 However, our study will require replication
in larger cross-sectional and longitudinal numbers.
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Additional Supporting Information may be found in the
online version of this article at the publisher’s website.
FIG. 1. (A) Left: Cats-and-Dogs test, example skewed image. A dog is shown. Images in this task varied in the amount of skew, and performance
at each level of skew was recorded. Right: control task, example image with added visual noise. A cat is shown. Images in this task varied in the
amount of visual noise, and performance at each level of noise was recorded. (B) Method for determining performance in the Cats-and-Dogs test;
psychophysical curves for 2 example participants are shown, one with PD (black), one without (gray). Percentage correct is shown for each level of
skew. Performance is defined as the skew level corresponding to 75% (midway between perfect 100% and guess at 50%) and is marked for each
of the participants. The same method was used to determine performance in the control task, with amount of noise plotted against percentage cor-
rect. (arbitrary units [a.u.]). (C) Left: performance in the Cats-and-Dogs test in patients with Parkinson’s disease and controls. Patients with Parkin-
son’s disease performed worse than healthy controls, with lower thresholds to correctly identify skewed images. Wider variation in performance was
also seen in patients with Parkinson’s disease. Right: performance in the control test in patients with Parkinson’s disease and controls. There was
no significant difference in performance in this task between patients with Parkinson’s disease and healthy controls. (a.u.). (D) Relationship between
performance in the Cats-and-Dogs test and overall cognition (Montreal Cognitive Assessment).
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